tbuckley/cabot-search huggingface dataset:
Efficacy of Cognitive Behaviour Therapy versus Anxiety Management for Body Dysmorphic Disorder: A Randomised Controlled Trial
Authors: David Veale, Martin Anson, Sarah Miles, Maria Pieta, Ana Costa, Nell Ellison
Journal: Psychotherapy and Psychosomatics (2014)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; The evidence base for the efficacy of cognitive behaviour therapy (CBT) for treating body dysmorphic disorder (BDD) is weak. &lt;b&gt;&lt;i&gt;Aims:&lt;/i&gt;&lt;/b&gt; To determine whether CBT is more effective than anxiety management (AM) in an outpatient setting. &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; This was a single-blind stratified parallel-group randomised controlled trial. The primary endpoint was at 12 weeks, and the Yale-Brown Obsessive Compulsive Scale for BDD (BDD-YBOCS) was the primary outcome measure. Secondary measures for BDD included the Brown Assessment of Beliefs Scale (BABS), the Appearance Anxiety Inventory (AAI) and the Body Image Quality of Life Inventory (BIQLI). The outcome measures were collected at baseline and week 12. The CBT group, unlike the AM group, had 4 further weekly sessions that were analysed for their added value. Both groups then completed measures at their 1-month follow-up. Forty-six participants with a DSM-IV diagnosis of BDD, including those with delusional BDD, were randomly allocated to either CBT or AM. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; At 12 weeks, CBT was found to be significantly superior to AM on the BDD-YBOCS [β = -7.19; SE (β) = 2.61; p &lt; 0.01; 95% CI = -12.31 to -2.07; d = 0.99] as well as the secondary outcome measures of the BABS, AAI and BIQLI. Further benefits occurred by week 16 within the CBT group. There were no differences in outcome for those with delusional BDD or depression. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; CBT is an effective intervention for people with BDD even with delusional beliefs or depression and is more effective than AM over 12 weeks.
Purification of murine T cell growth factor. A lymphocyte mitogen with helper activity.
Authors: A Granelli-Piperno, J D Vassalli, E Reich
Journal: The Journal of Experimental Medicine (1981)

Mouse T cell growth factor was purified from the serum-free conditioned medium of lectin-stimulated spleen cells. A 3,000-fold purification was achieved with a final yield of 12%. The purified protein, with an apparent Mr of 23,000 by sodium dodecyl sulfate polyacrylamide gel electrophoresis, was active at concentrations of 4 x 10(-11) M, both in the T cell growth factor and T cell replacing factor assays. In addition, purified T cell growth factor alone was mitogenic for spleen cells from both nude and normal mice.
The possible biological and reproductive functions of ubiquitin
Authors: C Bebington, F J Doherty, S D Fleming
Journal: Human Reproduction Update (2001)

The protein ubiquitin (Ub) appears to be present in all eukaryotic cells. Its widespread presence and extremely conserved structure indicate that it may play a vital role in cell metabolism. The roles of Ub are mediated by its covalent attachment to target proteins, a process known as ubiquitylation, a form of protein modification which may lead to degradation of the modified protein. A number of proteins with similar structure to Ub but varying in function have been isolated. Recently, there has been much interest in the role of Ub and its related proteins in reproductive processes. Ub and Ub-related proteins may be involved in gametogenesis, modulation of steroid receptor concentrations, placental development and endometrial modification at the beginning of pregnancy. These wide-ranging effects have led to extensive research which will be reviewed in this article.
The grammar of agrammatism
Authors: Dieter Hillert
Journal: Behavioral and Brain Sciences (2000)

There are reasons for reservations with respect to the postulated function of Broca's area. Evidence for the psychological reality of the relevant traces does not exist. In addition, because the syntax of non- (or partly) configurational languages is not described in terms of empty categories, no receptive agrammatism should be observed in these languages. Aphasia should not be examined in isolation from its cognitive components.
Outpatient clinic: where is the delay?
Authors: H R H Patel, C N Luxman, T S Bailey, J D M Brunning, D Zemmel, L K Morrell, M S Nathan, R A Miller
Journal: Journal of the Royal Society of Medicine (2002)

In outpatient clinics, consultation times are often eroded by extraneous activities. We measured the components of each outpatient episode in 167 patients attending a general urology follow-up clinic. 41% of time in the clinic was spent away from the patient-administration 17%, disturbances 15%, finding results 9%. The inefficiencies had changed little since a study in the same setting thirteen years earlier. Since then, parallel nurse-practitioner-run clinics have been introduced in the hope of giving consultants longer with the patient; however, time with each patient is now 4.8 min compared with a previous 7.6 min. The most easily addressed inefficiencies are those relating to missing information, such as radiology reports.
Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary
Authors: George Pentheroudakis, Nicholas Pavlidis, George Fountzilas, Dimitrios Krikelis, Anna Goussia, Aikaterini Stoyianni, Mats Sanden, Brianna St Cyr, Noga Yerushalmi, Hila Benjamin, Eti Meiri, Ayelet Chajut, Shai Rosenwald, Ranit Aharonov, Yael Spector
Journal: Molecular Cancer (2013)

Abstract Background Cancer of unknown or uncertain primary is a major diagnostic and clinical challenge, since identifying the tissue-of-origin of metastases is crucial for selecting optimal treatment. MicroRNAs are a family of non-coding, regulatory RNA molecules that are tissue-specific, with a great potential to be excellent biomarkers. Methods In this study we tested the performance of a microRNA-based assay in formalin-fixed paraffin-embedded samples from 84 CUP patients. Results The microRNA based assay agreed with the clinical diagnosis at presentation in 70% of patients; it agreed with the clinical diagnosis obtained after patient management, taking into account response and outcome data, in 89% of patients; it agreed with the final clinical diagnosis reached with supplemental immunohistochemical stains in 92% of patients, indicating a 22% improvement in agreement from diagnosis at presentation to the final clinical diagnosis. In 18 patients the assay disagreed with the presentation diagnosis and was in agreement with the final clinical diagnosis, which may have resulted in the administration of more effective chemotherapy. In three out of four discordant cases in which supplemental IHC was performed, the IHC results validated the assay’s molecular diagnosis. Conclusions This novel microRNA-based assay shows high accuracy in identifying the final clinical diagnosis in a real life CUP patient cohort and could be a useful tool to facilitate administration of optimal therapy.
Na,K-ATPase Gene Transfer Increases Liquid Clearance during Ventilation-induced Lung Injury
Authors: Yochai Adir, Phillip Factor, Vidas Dumasius, Karen M. Ridge, Jacob I. Sznajder
Journal: American Journal of Respiratory and Critical Care Medicine (2003)

Mechanical ventilation with high tidal volumes (HVT) downregulates alveolar Na,K-ATPase function and impairs lung liquid clearance. We hypothesized that overexpression of Na,K-ATPase in the alveolar epithelium could counterbalance these changes and increase clearance in a rat model of mild ventilation-induced lung injury. We used a surfactant-based system to deliver 4 x 10(9) plaque-forming units of E1a-/E3- recombinant adenovirus containing either a rat beta1 Na,K-ATPase subunit cDNA (adbeta1) or no cDNA (adnull) to rat lungs 7 days before ventilation with a VT of approximately 40 ml/kg (peak airway pressure of less than 35 cm H2O) for 40 minutes. Lung liquid clearance and Na, K-ATPase activity and protein abundance were increased in HVT adbeta1-infected lungs as compared with sham and adnull-infected HVT lungs. These results suggest that Na,K-ATPase subunit gene overexpression in the alveolar epithelium increases Na,K-ATPase function and lung liquid clearance in a model of HVT. We provide here the first evidence that using a genetic approach improves active Na+ transport and thus liquid clearance in the setting of mild ventilation-induced lung injury.
Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial
Authors: P. B. Panici, S. Basile, F. Maneschi, A. A. Lissoni, M. Signorelli, G. Scambia, R. Angioli, S. Tateo, G. Mangili, D. Katsaros, G. Garozzo, E. Campagnutta, N. Donadello, S. Greggi, M. Melpignano, F. Raspagliesi, N. Ragni, G. Cormio, R. Grassi, M. Franchi, D. Giannarelli, R. Fossati, V. Torri, M. Amoroso, C. Croce, C. Mangioni
Journal: JNCI Journal of the National Cancer Institute (2008)

Pelvic lymph nodes are the most common site of extrauterine tumor spread in early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been addressed in randomized studies. We conducted a randomized clinical trial to determine whether the addition of pelvic systematic lymphadenectomy to standard hysterectomy with bilateral salpingo-oophorectomy improves overall and disease-free survival. From October 1, 1996, through March 31, 2006, 514 eligible patients with preoperative International Federation of Gynecology and Obstetrics stage I endometrial carcinoma were randomly assigned to undergo pelvic systematic lymphadenectomy (n = 264) or no lymphadenectomy (n = 250). Patients’ clinical data, pathological tumor characteristics, and operative and early postoperative data were recorded at discharge from hospital. Late postoperative complications, adjuvant therapy, and follow-up data were collected 6 months after surgery. Survival was analyzed by use of the log-rank test and a Cox multivariable regression analysis. All statistical tests were two-sided. The median number of lymph nodes removed was 30 (interquartile range = 22–42) in the pelvic systematic lymphadenectomy arm and 0 (interquartile range = 0–0) in the no-lymphadenectomy arm ( P < .001). Both early and late postoperative complications occurred statistically significantly more frequently in patients who had received pelvic systematic lymphadenectomy (81 patients in the lymphadenectomy arm and 34 patients in the no-lymphadenectomy arm, P = .001). Pelvic systematic lymphadenectomy improved surgical staging as statistically significantly more patients with lymph node metastases were found in the lymphadenectomy arm than in the no-lymphadenectomy arm (13.3% vs 3.2%, difference = 10.1%, 95% confidence interval [CI] = 5.3% to 14.9%, P < .001). At a median follow-up of 49 months, 78 events (ie, recurrence or death) had been observed and 53 patients had died. The unadjusted risks for first event and death were similar between the two arms (hazard ratio [HR] for first event = 1.10, 95% CI = 0.70 to 1.71, P = .68, and HR for death = 1.20, 95% CI = 0.70 to 2.07, P = .50). The 5-year disease-free and overall survival rates in an intention-to-treat analysis were similar between arms (81.0% and 85.9% in the lymphadenectomy arm and 81.7% and 90.0% in the no-lymphadenectomy arm, respectively). Although systematic pelvic lymphadenectomy statistically significantly improved surgical staging, it did not improve disease-free or overall survival.
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Authors: Takashi Ishida, Tatsuro Joh, Naokuni Uike, Kazuhito Yamamoto, Atae Utsunomiya, Shinichiro Yoshida, Yoshio Saburi, Toshihiro Miyamoto, Shigeki Takemoto, Hitoshi Suzushima, Kunihiro Tsukasaki, Kisato Nosaka, Hiroshi Fujiwara, Kenji Ishitsuka, Hiroshi Inagaki, Michinori Ogura, Shiro Akinaga, Masao Tomonaga, Kensei Tobinai, Ryuzo Ueda
Journal: Journal of Clinical Oncology (2012)

Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options. Because CC chemokine receptor 4 (CCR4) is expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the treatment of patients with relapsed ATL.A multicenter phase II study of KW-0761 for patients with relapsed, aggressive CCR4-positive ATL was conducted to evaluate efficacy, pharmacokinetic profile, and safety. The primary end point was overall response rate, and secondary end points included progression-free and overall survival from the first dose of KW-0761. Patients received intravenous infusions of KW-0761 once per week for 8 weeks at a dose of 1.0 mg/kg.Of 28 patients enrolled onto the study, 27 received at least one infusion of KW-0761. Objective responses were noted in 13 of 26 evaluable patients, including eight complete responses, with an overall response rate of 50% (95% CI, 30% to 70%). Median progression-free and overall survival were 5.2 and 13.7 months, respectively. The mean half-life period after the eighth infusion was 422 ± 147 hours (± standard deviation). The most common adverse events were infusion reactions (89%) and skin rashes (63%), which were manageable and reversible in all cases.KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile. Further investigation of KW-0761 for treatment of ATL and other T-cell neoplasms is warranted.
Feasibility of Closed-Loop Insulin Delivery in Type 2 Diabetes: A Randomized Controlled Study
Authors: Kavita Kumareswaran, Hood Thabit, Lalantha Leelarathna, Karen Caldwell, Daniela Elleri, Janet M. Allen, Marianna Nodale, Malgorzata E. Wilinska, Mark L. Evans, Roman Hovorka
Journal: Diabetes Care (2013)

OBJECTIVE Closed-loop insulin delivery offers a promising treatment option, but to date, it has only been evaluated in type 1 diabetes. Our aim was to evaluate the feasibility of fully closed-loop subcutaneous insulin delivery in insulin-naïve patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Twelve subjects (seven males, age 57.2 years, BMI 30.5 kg/m2) with noninsulin-treated type 2 diabetes (HbA1c 8.4% [68 mmol/mol], diabetes duration 7.6 years) underwent two 24-h visits (closed-loop and control) in a randomized crossover design. During closed-loop visits, the subjects’ routine diabetes therapy was replaced with model predictive control algorithm-driven subcutaneous insulin pump delivery based on real-time continuous glucose monitoring. Meals were unannounced, and no additional insulin was administered for carbohydrates consumed. During control visits, the usual diabetes regimen was continued (metformin 92%, sulfonylureas 58%, dipeptidyl peptidase-4 inhibitors 33%). On both visits, subjects consumed matched 50- to 80-g carbohydrate meals and optional 15-g carbohydrate snacks and remained largely sedentary. Plasma glucose measurements evaluated closed-loop performance. RESULTS Compared with conventional therapy, 24 h of closed-loop insulin delivery increased overall the median time in target plasma glucose (3.9–8.0 mmol/L) from 24 to 40% (P = 0.016), despite sensor under-reading by a median of 1.2 mmol/L. The benefit of the closed-loop system was more prominent overnight, with greater time in target glucose (median 78 vs. 35%; P = 0.041) and less time in hyperglycemia (22 vs. 65%; P = 0.041). There was no hypoglycemia during either intervention. CONCLUSIONS A closed-loop system without meal announcement and using subcutaneous insulin delivery in insulin-naïve patients with type 2 diabetes appears feasible and safe. Improvement in postprandial glucose control may require further optimization of system performance.
Which determinants predict tibiofemoral and patellofemoral osteoarthritis after anterior cruciate ligament injury? A systematic review
Authors: Belle L van Meer, Duncan E Meuffels, Wilbert A van Eijsden, Jan A N Verhaar, Sita M A Bierma-Zeinstra, Max Reijman
Journal: British Journal of Sports Medicine (2015)

Background Anterior cruciate ligament (ACL) injury is an important risk factor for development of knee osteoarthritis (OA). To identify those ACL injured patients at increased risk for knee OA, it is necessary to understand risk factors for OA. Aim To summarise the evidence for determinants of (1) tibiofemoral OA and (2) patellofemoral OA in ACL injured patients. Methods MEDLINE, EMBASE, Web of Science and CINAHL databases were searched up to 20 December 2013. Additionally, reference lists of eligible studies were manually and independently screened by two reviewers. 2348 studies were assessed for the following main inclusion criteria: ≥20 patients; ACL injured patients treated operatively or non-operatively; reporting OA as outcome; description of relationship between OA outcome and determinants; and a follow-up period ≥2 years. Two reviewers extracted the data, assessed the risk of bias and performed a best-evidence synthesis. Results Sixty-four publications were included and assessed for quality. Two studies were classified as low risk of bias. Medial meniscal injury/meniscectomy showed moderate evidence for influencing OA development (tibiofemoral OA and compartment unspecified). Lateral meniscal injury/meniscectomy showed moderate evidence for no relationship (compartment unspecified), as did time between injury and reconstruction (tibiofemoral and patellofemoral OA). Conclusions Medial meniscal injury/meniscectomy after ACL rupture increased the risk of OA development. In contrast, it seems that lateral meniscal injury/meniscectomy has no relationship with OA development. Our results suggest that time between injury and reconstruction does not influence patellofemoral and tibiofemoral OA development. Many determinants showed conflicting and limited evidence and no determinant showed strong evidence.
Microvascular Structural Correlates of Myocardial Contrast Echocardiography in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Authors: Sarah Shimoni, Nikolaos G. Frangogiannis, Constadina J. Aggeli, Kesavan Shan, Miguel A. Quinones, Rafael Espada, George V. Letsou, Gerald M. Lawrie, William L. Winters, Michael J. Reardon, William A. Zoghbi
Journal: Circulation (2002)

Background— Myocardial contrast echocardiography (MCE) has been used to evaluate myocardial viability. There are no data, however, on the pathological determinants of myocardial perfusion by MCE in humans and the implications of such determinants. Methods and Results— MCE was performed in 20 patients with coronary artery disease and ventricular dysfunction within 24 hours before myocardial biopsy at surgery using a continuous Optison infusion (12 to 16 cc/h), with intermittent pulse inversion harmonics and incremental triggering. Peak myocardial contrast intensity (MCI) and the rate of increase in MCI (β) were quantitated. Thirty-six transmural myocardial biopsies (2 per patient) were obtained by transesophageal echocardiography. Total microvascular (&lt;100 μm) density, capillary density and area, arteriolar and venular density, and percent collagen content were quantitated with immunohistochemistry. Peak MCI correlated with microvascular density ( r =0.59, P &lt;0.001) and capillary area ( r =0.64, P &lt;0.001) and inversely correlated with percent collagen content ( r =−0.45, P =&lt;0.01). The best relation was observed when the ratio of peak MCI in the 2 biopsied segments in each patient was compared with the ratio of microvascular density and capillary area ( r =0.84 and 0.87, respectively; P &lt;0.001). A significant overlap in microvascular density was seen between segments with and without recovery of function. The new MCE indices of blood velocity (β) and flow (peak MCI×β) better identified recovery of function compared with microvascular density and the sole use of peak MCI. Conclusions— Microvascular integrity is a significant determinant of maximal MCI in humans. MCE indices of blood velocity and flow are important parameters that predict recovery of function after revascularization.
IgE-Binding Capacity and Cross-Reactivity of Lipid-Transfer-Proteins (LTP) from Peach (Pru p 3) and Hazelnut (Cor a 8)
Authors: C. Hartz, I. Lauer, J. Lidholm, K. Fötisch, M. San Miguel-Moncin, A. Cistero-Bahima, S. Vieths, S. Scheurer
Journal: Journal of Allergy and Clinical Immunology (2006)
Sociological implications of an epidemiological study of eczema in the City of Birmingham
Authors: N.C. BOWKER, K.W. CROSS, E.A. FAIRBURN, M. WALL
Journal: British Journal of Dermatology (1976)

An epidemiological study has been made of 4696 cases of eczematous dermatitis referred to hospital outpatient clinics in the City of Birmingham over a 3‐year period. Some sociological implications of the investigation are discussed. The need for further sociological accounts of skin disease is stressed.
Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice
Authors: Eva L Kneepkens, Chamaida Plasencia, Charlotte LM Krieckaert, Dora Pascual-Salcedo, Desiree van der Kleij, Michael T Nurmohamed, M Teresa López-Casla, Roeland Wieringa, Theo Rispens, Gertjan Wolbink
Journal: Annals of the Rheumatic Diseases (2014)

Tumour necrosis factor inhibitors (TNFi) are effective in the majority of patients with rheumatoid arthritis (RA),1 however, an important reason for non-response is low drug level due to immunogenicity.2 To our knowledge, no data collected during a prospective observational study is currently available regarding the relationship between golimumab level, immunogenicity and response in RA.

This prospective observational cohort consisted of 37 consecutive adult patients with RA, according to the American College of Rheumatology 1987 revised criteria,3 in whom golimumab 50 mg subcutaneously once monthly was initiated according to the judgment of the rheumatologist, and who were recruited from two departments (Spain and The Netherlands). The study was approved by both Medical Ethics Committees. Clinical response was defined as Disease Activity Score using 28 joint count (DAS28) <3.2, calculated with erythrocyte sedimentation rate (ESR) (mm/h). Patients were eligible for inclusion when clinical data and sera of baseline with ≥ one follow-up visit were available.

Clinical measurements and trough-level sera were collected at baseline and 4, 16, 28 and 52 weeks (The Netherlands), or half yearly (Spain), thereafter. Golimumab levels were measured analogously to adalimumab4 using TNF for capture and rabbit antigolimumab for detection …